ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 14

Individual RA-Derived Monoclonal Anti-Citrullinated Protein Autoantibodies (ACPA) Have Extensive Citrulline Multi-Reactivity Demonstrated By a Large-Scale Protein Array Platform

Peter Sahlström1, Johanna Steen1, Madeleine Jenning2, Philip J. Titcombe1,3, Ute Nonhoff4,5, Ragnhild Stålesen6, Bianka Marklein2, Daniel L. Mueller3, Zoltan Konthur4, Karin Lundberg7, Anca I. Catrina6, Lars Klareskog1, Vivianne Malmström1, Karl Skriner2 and Caroline Grönwall8, 1Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Dept. of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, 3The Center for Immunology, Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, 4Engine GmbH, Hennigsdorf, Germany, 5Max Planck Institute of Colloids and Interfaces, Potsdam, Germany, 6Rheumatology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 7Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 8Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: ACPA, anti-CCP antibodies, autoantibodies and rheumatoid arthritis (RA), B cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

The presence of serum IgG anti-citrullinated protein autoantibodies (ACPA) in rheumatoid arthritis (RA), is associated with more aggressive disease progression. Although ACPA have been suggested to be important in the pathogenesis, the mechanisms and pathogenic targets are still poorly described. ACPA multi-reactivity to synthetically citrullinated peptides have been reported, yet how this corresponds to ACPA full-length protein targeting have not previously been explored. Here we used a novel protein array approach to investigate the citrulline reactivity broadness of three single-cell derived ACPA monoclonal antibodies (mAbs) compared to polyclonal IgG anti-CCP2.

Methods:

The macroarray platform (hEXselect, Engine) consists of 20 776 E.coli on-array expressed protein fragments from 6 909 genes with between 1-37 fragments for each gene. All originating from human fetal brain cDNA, cloned into an IPTG inducible vector with N-terminal RGS-His6-Tag as expression control. The array was enzymatically citrullinated with rabbit PAD. Duplicated spotting and alkaline phosphatase conjugated anti-human IgG (Fc) with AttoPhos substrate enabled reliable spectral fluorescent intensity detection that were scored from 0-3 using a grid based analyzing software. Binding of two recombinant ACPA mAbs derived from RA synovial plasma cells (1325:01B09 and 1325:04C03) and one mAb derived from tetramer sorted blood memory cells (37CEPT2C04) were evaluated. The technology was validated with ELISA and Western blot using individually expressed selected protein fragments.

Results:

Purified polyclonal IgG anti-CCP2 from ACPA+ RA patients contained, as expected, reactivity to a range of citrullinated full-length proteins and protein fragments (674 total hits, 154 with visual scoring 3). However, interestingly, the individually analyzed monoclonal ACPA also displayed reactivity to a large number of citrullinated targets. While some shared targets were identified, also unique mAb-specific antibody targets were detected. The ACPA mAb 1325:01B09 reacted to in total 1790 citrullinated protein fragments (1328 mAb-unique; 190 with visual scoring 3), 1325:04C03 reacted to 408 (115 mAb-unique; 42 with visual scoring 3), and 37CEPT2C04 reacted to 792 (487 mAb-unique; 118 with visual scoring 3). Reactivity to native unmodified proteins were limited (53, 19, or 22 hits, respectively). Among the identified proteins were known targets e.g. Cit-vimentin, Cit-hnRNPs, and Cit-histones, as well as less studied RA autoimmunity targets e.g. Cit-40S ribosomal proteins.

Conclusion:

All investigated monoclonal ACPA were multi-reactive to citrullinated protein targets to a much larger extent than previously described and bound hundreds of full-length proteins and protein fragments. Nevertheless, ACPA mAbs demonstrate individual distinct binding patterns. Further studies on how ACPA bind to proteins in cells during physiological citrullination and the clinical relevance of ACPA multi-reactivity will be of importance.


Disclosure: P. Sahlström, None; J. Steen, None; M. Jenning, None; P. J. Titcombe, None; U. Nonhoff, Engine GmbH, 3; R. Stålesen, None; B. Marklein, None; D. L. Mueller, None; Z. Konthur, Engine GmbH, 3; K. Lundberg, None; A. I. Catrina, None; L. Klareskog, None; V. Malmström, None; K. Skriner, None; C. Grönwall, None.

To cite this abstract in AMA style:

Sahlström P, Steen J, Jenning M, Titcombe PJ, Nonhoff U, Stålesen R, Marklein B, Mueller DL, Konthur Z, Lundberg K, Catrina AI, Klareskog L, Malmström V, Skriner K, Grönwall C. Individual RA-Derived Monoclonal Anti-Citrullinated Protein Autoantibodies (ACPA) Have Extensive Citrulline Multi-Reactivity Demonstrated By a Large-Scale Protein Array Platform [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/individual-ra-derived-monoclonal-anti-citrullinated-protein-autoantibodies-acpa-have-extensive-citrulline-multi-reactivity-demonstrated-by-a-large-scale-protein-array-platform/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/individual-ra-derived-monoclonal-anti-citrullinated-protein-autoantibodies-acpa-have-extensive-citrulline-multi-reactivity-demonstrated-by-a-large-scale-protein-array-platform/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology